Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Technology for preparing anti influenza virus transfer factors

An anti-influenza virus and transfer factor technology, applied in the direction of antiviral agents, medical preparations containing active ingredients, peptide/protein components, etc. problem, to achieve the effect of easy source, no adverse reactions, and long maintenance time

Inactive Publication Date: 2007-10-24
ZHAOQING UNIV
View PDF2 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The content of the above patent application is to directly filter and extract the broken tissue after freezing and centrifuging, which also has the defect of incomplete cell crushing, and the process is cumbersome, the time is long, and the activity loss of the product is also large. Therefore, the yield It is difficult to improve (the above patent application does not provide data analysis for the actual extraction product)
[0006] Porcine spleen and thymus are places where immunocompetent cells gather, and the sources of materials are very extensive. Therefore, it is of great theoretical and practical significance to extract specific transfer factors from these cells, but it has not been reported yet.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1: Preparation of anti-influenza virus transfer factor

[0025] A kind of preparation technology of anti-influenza virus transfer factor of the present invention comprises the following steps:

[0026] (1) Preparation of raw materials: 10 healthy 6-month-old pigs with no medical history were selected and immunized with influenza virus vaccine subcutaneously at a dose of 1 unit / 100kg. After 15 days, they were immunized again with the same dose as above. They were slaughtered 15-20 days after the second immunization, and the spleen and thymus were taken out, stored on ice, and stored at -20°C for later use.

[0027] (2) Pretreatment: After weighing the pig spleen, wash the pig spleen with cold three-distilled water, cut off its fascia and adipose tissue with scissors, and then wash it with cold three-distilled water.

[0028] (3) Crushing: Cut the pig spleen washed above into pieces, add 2 times the volume of cold normal saline, and mash it with a high-speed tiss...

Embodiment 2

[0035] Embodiment two: the detection of the anti-influenza virus transfer factor prepared by the process of the present invention

[0036] The anti-influenza virus transfer factor (hereinafter referred to as "this product") prepared by the process described in Example 1 is detected as follows:

[0037] 1) Ultraviolet spectrophotometric measurement: This product has a high absorption peak at 250.0-252.0nm, and ABS260 / ABS280>2.0.

[0038] 2) The standard solution is light yellow and the pH value is between 6.0 and 6.5.

[0039] 3) 20% sulfosalicylic acid test: This product has no turbidity and precipitation, indicating that the protein reaction is negative, and it does not contain macromolecular proteins.

[0040] 4) Determination of peptide content: The peptide content of this product is 1.130 mg / ml as determined by the biuret method.

[0041] 5) Determination of nucleic acid content: The nucleic acid content of this product is 532.899 μg / ml as determined by the orcinol metho...

Embodiment 3

[0047] Embodiment three: the application of the anti-influenza virus transfer factor prepared by the process of the present invention

[0048] The anti-influenza virus transfer factor solution prepared in Example 1 was added 15% syrup and standard preservatives, such as 0.25% sodium benzoate, according to the requirements of oral liquid, and then divided into 10ml / bottles.

[0049] In addition to the above syrup dosage form, the anti-influenza virus transfer factor of the present invention can also be made into other oral liquids.

[0050] In addition, the powder of the anti-influenza virus transfer factor can be further obtained through a conventional freeze-drying process, and combined with conventional auxiliary materials, it can be made into dosage forms such as capsules and tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a method for preparing anti-influenza virus transfer factor, comprising following steps: preparing raw material, pre-treating, disintegrating, freezing and thawing, extracting, ultra-filtering, disinfecting and packing. The invention employs process of first immune and second extraction. The preparation time is reduced because of low-temperature freezing and thawing and hollow fiber tube ultra-filtering, so the substance activity will not be destroyed. It can be made into oral liquid.

Description

technical field [0001] The invention belongs to the field of medicines and preparations thereof, and relates to a new dosage form of ginseng polysaccharide and a related preparation process. Background technique [0002] Influenza is called flu for short, is the acute respiratory infectious disease that is caused by influenza virus. Influenza and general viral influenza are two diseases caused by different pathogens. After the general pathogenic virus invades the respiratory mucosa, the antiviral antibody will neutralize it, which can play a role in avoiding infection to a certain extent. The pathogen that causes influenza is influenza virus. The biggest characteristic of influenza virus is that it is easy to mutate, causing the anti-influenza virus-specific antibodies that have appeared in the human body to lose the effect of neutralizing the virus, thus making people susceptible to infection and even causing large-scale epidemics. After the patient is infected by influe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/28A61K38/02A61P31/16C07K1/14A61K35/26
Inventor 李充璧李湘乐王燕萍黄丽华温虎成邵玲郭雁君李芸瑛
Owner ZHAOQING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com